Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Enterotoxigenic Escherichia coli-blood group A interactions intensify diarrheal severity.

Kumar P, Kuhlmann FM, Chakraborty S, Bourgeois AL, Foulke-Abel J, Tumala B, Vickers TJ, Sack DA, DeNearing B, Harro CD, Wright WS, Gildersleeve JC, Ciorba MA, Santhanam S, Porter CK, Gutierrez RL, Prouty MG, Riddle MS, Polino A, Sheikh A, Donowitz M, Fleckenstein JM.

J Clin Invest. 2019 Jul 1;129(7):2980. doi: 10.1172/JCI130874. Epub 2019 Jul 1. No abstract available.

2.

Hyperimmune bovine colostral anti-CS17 antibodies protect against enterotoxigenic Escherichia coli diarrhea in a randomized, doubled-blind, placebo-controlled human infection model.

Savarino SJ, McKenzie R, Tribble DR, Porter CK, O'Dowd A, Sincock SA, Poole ST, DeNearing B, Woods CM, Kim H, Grahek SL, Brinkley C, Crabb JH, Bourgeois AL.

J Infect Dis. 2019 Mar 21. pii: jiz135. doi: 10.1093/infdis/jiz135. [Epub ahead of print]

PMID:
30897198
3.

Live attenuated enterotoxigenic Escherichia coli (ETEC) vaccine with dmLT adjuvant protects human volunteers against virulent experimental ETEC challenge.

Harro C, Louis Bourgeois A, Sack D, Walker R, DeNearing B, Brubaker J, Maier N, Fix A, Dally L, Chakraborty S, Clements JD, Saunders I, Darsley MJ.

Vaccine. 2019 Mar 28;37(14):1978-1986. doi: 10.1016/j.vaccine.2019.02.025. Epub 2019 Feb 21.

4.

Enterotoxigenic E. coli virulence gene regulation in human infections.

Crofts AA, Giovanetti SM, Rubin EJ, Poly FM, GutiƩrrez RL, Talaat KR, Porter CK, Riddle MS, DeNearing B, Brubaker J, Maciel M Jr, Alcala AN, Chakraborty S, Prouty MG, Savarino SJ, Davies BW, Trent MS.

Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):E8968-E8976. doi: 10.1073/pnas.1808982115. Epub 2018 Aug 20.

5.

Human Experimental Challenge With Enterotoxigenic Escherichia coli Elicits Immune Responses to Canonical and Novel Antigens Relevant to Vaccine Development.

Chakraborty S, Randall A, Vickers TJ, Molina D, Harro CD, DeNearing B, Brubaker J, Sack DA, Bourgeois AL, Felgner PL, Liang X, Mani S, Wenzel H, Townsend RR, Gilmore PE, Darsley MJ, Rasko DA, Fleckenstein JM.

J Infect Dis. 2018 Sep 22;218(9):1436-1446. doi: 10.1093/infdis/jiy312.

PMID:
29800314
6.

Enterotoxigenic Escherichia coli-blood group A interactions intensify diarrheal severity.

Kumar P, Kuhlmann FM, Chakraborty S, Bourgeois AL, Foulke-Abel J, Tumala B, Vickers TJ, Sack DA, DeNearing B, Harro CD, Wright WS, Gildersleeve JC, Ciorba MA, Santhanam S, Porter CK, Gutierrez RL, Prouty MG, Riddle MS, Polino A, Sheikh A, Donowitz M, Fleckenstein JM.

J Clin Invest. 2018 Aug 1;128(8):3298-3311. doi: 10.1172/JCI97659. Epub 2018 Jun 25. Erratum in: J Clin Invest. 2019 Jul 1;129(7):2980.

7.

Impact of lower challenge doses of enterotoxigenic Escherichia coli on clinical outcome, intestinal colonization and immune responses in adult volunteers.

Chakraborty S, Harro C, DeNearing B, Brubaker J, Connor S, Maier N, Dally L, Flores J, Bourgeois AL, Walker R, Sack DA.

PLoS Negl Trop Dis. 2018 Apr 27;12(4):e0006442. doi: 10.1371/journal.pntd.0006442. eCollection 2018 Apr.

8.

Clinical endpoints in the controlled human challenge model for Shigella: A call for standardization and the development of a disease severity score.

Porter CK, Lynen A, Riddle MS, Talaat K, Sack D, GutiƩrrez RL, McKenzie R, DeNearing B, Feijoo B, Kaminski RW, Taylor DN, Kirkpatrick BD, Bourgeois AL.

PLoS One. 2018 Mar 28;13(3):e0194325. doi: 10.1371/journal.pone.0194325. eCollection 2018.

9.

Campylobacter jejuni transcriptional and genetic adaptation during human infection.

Crofts AA, Poly FM, Ewing CP, Kuroiwa JM, Rimmer JE, Harro C, Sack D, Talaat KR, Porter CK, Gutierrez RL, DeNearing B, Brubaker J, Laird RM, Maue AC, Jaep K, Alcala A, Tribble DR, Riddle MS, Ramakrishnan A, McCoy AJ, Davies BW, Guerry P, Trent MS.

Nat Microbiol. 2018 Apr;3(4):494-502. doi: 10.1038/s41564-018-0133-7. Epub 2018 Mar 27.

10.

Rifaximin Fails to Prevent Campylobacteriosis in the Human Challenge Model: A Randomized, Double-Blind, Placebo-Controlled Trial.

Rimmer JE, Harro C, Sack DA, Talaat KR, Gutierrez RL, DeNearing B, Brubaker J, Laird RM, Poly F, Maue AC, Jaep K, Alcala A, Mochalova Y, Gariepy CL, Chakraborty S, Guerry P, Tribble DR, Porter CK, Riddle MS.

Clin Infect Dis. 2018 Apr 17;66(9):1435-1441. doi: 10.1093/cid/cix1014.

PMID:
29145631
11.

Prophylactic Efficacy of Hyperimmune Bovine Colostral Antiadhesin Antibodies Against Enterotoxigenic Escherichia coli Diarrhea: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial.

Savarino SJ, McKenzie R, Tribble DR, Porter CK, O'Dowd A, Cantrell JA, Sincock SA, Poole ST, DeNearing B, Woods CM, Kim H, Grahek SL, Brinkley C, Crabb JH, Bourgeois AL.

J Infect Dis. 2017 Jul 1;216(1):7-13. doi: 10.1093/infdis/jix144.

PMID:
28541500
12.

An Evidenced-Based Scale of Disease Severity following Human Challenge with Enteroxigenic Escherichia coli.

Porter CK, Riddle MS, Alcala AN, Sack DA, Harro C, Chakraborty S, Gutierrez RL, Savarino SJ, Darsley M, McKenzie R, DeNearing B, Steinsland H, Tribble DR, Bourgeois AL.

PLoS One. 2016 Mar 3;11(3):e0149358. doi: 10.1371/journal.pone.0149358. eCollection 2016.

13.

Evaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult Subjects.

Chakraborty S, Harro C, DeNearing B, Bream J, Bauers N, Dally L, Flores J, Van de Verg L, Sack DA, Walker R.

Clin Vaccine Immunol. 2016 Apr 4;23(4):315-25. doi: 10.1128/CVI.00608-15. Print 2016 Apr.

14.

Characterization of Mucosal Immune Responses to Enterotoxigenic Escherichia coli Vaccine Antigens in a Human Challenge Model: Response Profiles after Primary Infection and Homologous Rechallenge with Strain H10407.

Chakraborty S, Harro C, DeNearing B, Ram M, Feller A, Cage A, Bauers N, Bourgeois AL, Walker R, Sack DA.

Clin Vaccine Immunol. 2015 Nov 18;23(1):55-64. doi: 10.1128/CVI.00617-15. Print 2016 Jan.

15.

The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease.

Darsley MJ, Chakraborty S, DeNearing B, Sack DA, Feller A, Buchwaldt C, Bourgeois AL, Walker R, Harro CD.

Clin Vaccine Immunol. 2012 Dec;19(12):1921-31. doi: 10.1128/CVI.00364-12. Epub 2012 Oct 3.

16.

A combination vaccine consisting of three live attenuated enterotoxigenic Escherichia coli strains expressing a range of colonization factors and heat-labile toxin subunit B is well tolerated and immunogenic in a placebo-controlled double-blind phase I trial in healthy adults.

Harro C, Sack D, Bourgeois AL, Walker R, DeNearing B, Feller A, Chakraborty S, Buchwaldt C, Darsley MJ.

Clin Vaccine Immunol. 2011 Dec;18(12):2118-27. doi: 10.1128/CVI.05342-11. Epub 2011 Oct 12.

17.

Refinement of a human challenge model for evaluation of enterotoxigenic Escherichia coli vaccines.

Harro C, Chakraborty S, Feller A, DeNearing B, Cage A, Ram M, Lundgren A, Svennerholm AM, Bourgeois AL, Walker RI, Sack DA.

Clin Vaccine Immunol. 2011 Oct;18(10):1719-27. doi: 10.1128/CVI.05194-11. Epub 2011 Aug 18.

18.

Volunteer challenge with enterotoxigenic Escherichia coli that express intestinal colonization factor fimbriae CS17 and CS19.

McKenzie R, Porter CK, Cantrell JA, Denearing B, O'Dowd A, Grahek SL, Sincock SA, Woods C, Sebeny P, Sack DA, Tribble DR, Bourgeois AL, Savarino SJ.

J Infect Dis. 2011 Jul 1;204(1):60-4. doi: 10.1093/infdis/jir220.

19.

In a randomized, double-blinded, placebo-controlled trial, the single oral dose typhoid vaccine, M01ZH09, is safe and immunogenic at doses up to 1.7 x 10(10) colony-forming units.

Lyon CE, Sadigh KS, Carmolli MP, Harro C, Sheldon E, Lindow JC, Larsson CJ, Martinez T, Feller A, Ventrone CH, Sack DA, DeNearing B, Fingar A, Pierce K, Dill EA, Schwartz HI, Beardsworth EE, Kilonzo B, May JP, Lam W, Upton A, Budhram R, Kirkpatrick BD.

Vaccine. 2010 Apr 30;28(20):3602-8. doi: 10.1016/j.vaccine.2010.02.017. Epub 2010 Feb 24.

PMID:
20188175

Supplemental Content

Loading ...
Support Center